Abstract
Unfavourable pharmacokinetics is the major hurdle for the new chemical
entity (NCE) to become a drug during the drug discovery and development process.
Early evaluation of absorption, distribution, metabolism, and excretion (ADME)
characteristics for the promising candidates not only speed up the drug development
stages but also lower the attrition rate in clinical phases which can save resource and
time. Furthermore, pharmacokinetic behavior is helpful for a better understanding of
efficacy, toxicity, and safety. The present chapter deals with ADME information on
chromene-based molecules, which have gained significant importance nowadays due to
their wide range of pharmacological actions, including anticancer activities.
Comprehensive ADME data based on the available information on in-vitro and in-vivo
profiles will pave the way towards understanding for discovery and development of
new therapeutics in this scaffold from bench to bedside.
Keywords: 14n, ADL5859, ADME, Chromene, Crolibulin, C-8 hydroxychromene, Dihydropyrimidinone, Glabridin, IND8541, Methoxsalen, mHA11, Pharmacokinetics.
Related Journals
Current Clinical Pharmacology
Current Cancer Therapy Reviews
Current Nanomedicine
Current Psychopharmacology
Drug Delivery Letters
Letters in Drug Design & Discovery
Recent Advances in Anti-Infective Drug Discovery
Coronaviruses
Applied Drug Research, Clinical Trials and Regulatory Affairs
Anti-Infective Agents
Related Books
Medical Applications of Beta-Glucan
Postbiotics: Science, Technology and Applications
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceutical Chemistry and Production: An Introductory Textbook
Pharmaceuticals for Targeting Coronaviruses
New Findings from Natural Substances
Nanopharmacology and Nanotoxicology: Clinical Implications and Methods
Practice and Re-Emergence of Herbal Medicine
New Avenues in Drug Discovery and Bioactive Natural Products
Plant-derived Hepatoprotective Drugs